Abstract: Non-agglutinating .beta.-galactoside binding proteins (GBP), both the natural proteins and proteins produced by recombinant DNA technology, are provided for use as inhibitors and regulators of vertebrate cell growth and as anti-viral agents. Methods of producing the GBP's are also described. The GBP's show a powerful growth inhibitory effect against human cancer cells making them potentially useful therapeutic agents in the treatment of malignant disease and also show an inhibitory effect on viral replication making them potentially useful as anti-viral agents.

Abstract: Peptides derived from three regions of the lectin domain of GMP-140 (P-selectin) and the related selectins, ELAM-1 (E-selectin) and the lymphocyte homing receptor (L-selectin), have been found to inhibit neutrophil adhesion to GMP-140. These and additional peptides have been synthesized, having as their core region portions of the 74-76 amino acid sequence of GMP-140, with residue 1 defined as the N-terminus of the mature protein after the cleavage of the signal peptide. Examples demonstrate the inhibition of the binding of neutrophils to GMP-140 of peptides in concentrations ranging from 30 to 1500 .mu.mol. It has been found that alterations within the core sequence, as well as N-terminal and C-terminal flanking regions, do not result in loss of biological activity. The peptides are useful as diagnostics and, in combination with a suitable pharmaceutical carrier, for clinical applications in the modulation or inhibition of coagulation processes or inflammatory processes.

Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

Abstract: The invention relates generally to compositions of and methods for using polynucleotides encoding kappa opioid receptors. In addition to such polynucleotides themselves, the invention relates to expression vectors comprising polynucleotides encoding kappa opioid receptors, recombinant host cells comprising such polynucleotides, and processes for preparing kappa opioid receptor polypeptides.

Abstract: The invention provides a new human growth regulator protein (GRREG) and polynucleotides which identify and encode GRREG. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRREG.

Abstract: A novel subtype of the P.sub.2 -purinergic receptor, referred to as the P.sub.2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor and associated screening and therapeutic methods also are disclosed.

Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian receptor polypeptides, designated OCR1. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the MAMMALIAN OCR1 gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between MAMMALIAN OCR1 and agents that initiate signal transduction through binding to MAMMALIAN OCR1. In a specific embodiment, the MAMMALIAN OCR1 may HUMAN OCR1 or MOUSE OCR1.

Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.

Abstract: A gene encoding the human EP.sub.3 prostaglandin receptor has been cloned and sequenced. The protein encoded by this gene has seven transmembrane domains and is 81% homologous to the murine EP.sub.3 receptor. Two variants that differ in their carboxy terminal coding sequence, and one variant that differs in its 3' untranslated sequence only, have also been cloned. The proteins, when expressed in eukaryotic cells, are capable of binding prostaglandins and their agonists and regulating adenylate cyclase activity in response to prostaglandins.

Abstract: Disclosed are novel DNAs encoding polypeptides related to opioid receptors, methods for expressing and isolating such polypeptides, and methods of use thereof. Also disclosed are vectors for expressing the novel DNAs of the invention.

Abstract: GPR25 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing GPR25 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: Human G-protein parathyroid hormone (PTH) receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the PTH receptor receptor polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the PTH receptor receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

Abstract: The subject of the present invention is a DNA fragment which encodes a protein capable of being recognised by an antiserum against the transferrin receptor of the strain IM2394 or IM2169 of N. meningitidis as well as a process for producing the said protein by a recombinant route. By way of example, such a DNA fragment encodes the tbp1 subunit of the strain IM2394 or IM2169 or the tbp2 subunit of the strain IM2394 or IM2169.

Abstract: An assay for measuring activation (i.e., autophosphorylation) of a tyrosine kinase receptor of interest is disclosed. a) A first solid phase is coated with a substantially homogeneous population of cells so that the cells adhere to the first solid phase. The cells have either an endogenous tyrosine kinase receptor or have been transformed with DNA encoding a receptor or "receptor construct" and the DNA has been expressed so that the receptor or receptor construct is presented in the cell membranes of the cells. b) A ligand is then added to the solid phase having the adhering cells, such that the tyrosine kinase receptor is exposed to the ligand. c) Following exposure to the ligand, the adherent cells are solubilized, thereby releasing cell lysate. d) A second solid phase is coated with a capture agent which binds specifically to the tyrosine kinase receptor, or, in the case of a receptor construct to the flag polypeptide.

Abstract: The present invention provides for a screen for a polypeptide ligand that can bind to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor and that can promote a differential function and/or influence the phenotype, such as growth and/or proliferation, of cells that bear the receptor. The present invention also provides a method of screening for a molecule capable of competing with collagen for binding to the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor comprising contacting a sample suspected of containing the molecule with the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor in the presence of collagen under conditions in which the collagen is capable of binding to the extracellular domain and detecting binding of the molecule to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor extracellular domain. The invention further contemplates the utilization of collagen to support the growth, survival, or differentiation of Tyro-10 (DDR-2) or NEP (DDR-1) expressing cells.

Abstract: HFGAN72X polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HFGAN72X polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthema; Parkinson's disease; acute heart failure; hypotension; hypertension; unary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Abstract: The present invention provides novel human protein tyrosine phosphatases (HPTP) and polynucleotides which identify and encode HPTP. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTP and for a method of producing HPTP. The invention also provides for pharmaceutical compositions comprising HPTP or antagonists of HPTP, and antibodies which specifically bind HPTP. Additionally, the invention provides antisense molecules to HPTP for treatment or prevention of diseases associated with abnormal expression of HPTP.

Abstract: A recombinant non-glycosylated mammalian growth factor (BTC-GF) stimulates proliferation of human smooth muscle cells. Especially, the amino acid sequence of the protein deduced from the nucleotide sequence coding for human BTC-GF is as that comprising the amino acids No. 1 to No. 147 of FIG. 10 (SEQ ID NO:18) or the amino acids No. 1 to 80 of FIG. 10, (SEQ ID NO:18) and the amino acid sequence of the protein deduced from the nucleotide sequence coding for mouse BTC-GF is as that comprising the amino acids No. 1 to No. 146 of FIG. 9 (SEQ ID NO:17).

Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described art recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.

Abstract: Isolated DNAs encoding opiorph receptor polypeptides are provided. Recombinant cloning vectors which include these DNA sequences and cells which include these vectors are also provided. Methods for detecting the expression, in a tissue, of mRNA encoding a polypeptide encoded by this DNA are encompassed as well as methods for producing these polypeptides. These isolated polypeptides and antibodies to these polypeptides are also contemplated.